2.3 Disease Indications & the Cellular Therapy Modality Map
Key Takeaways
- Autologous HCT provides hematopoietic rescue after high-dose therapy for selected diseases; multiple myeloma, chemosensitive relapsed lymphoma and germ-cell tumors are major examples, but timing and eligibility depend on current disease guidance and alternatives.
- Allogeneic HCT adds donor hematopoiesis and immune effects for selected malignant, marrow-failure, immune, hemoglobin and inherited disorders; disease biology/MRD, donor/platform, non-relapse risk and patient goals shape the decision.
- CAR T-cell products targeting CD19 or BCMA are not interchangeable: construct, manufacturing, age range, disease indication, prior-therapy requirements, dosing, and toxicity instructions are all product-specific and change with supplemental approvals.
- The cellular-therapy category extends beyond CAR T cells to tumor-infiltrating lymphocytes, natural killer-cell approaches, bispecific antibodies, gene-modified hematopoietic cells, and donor lymphocyte infusions; their sources, manufacturing, administration, and toxicity patterns differ.
- A bispecific antibody is an administered drug that redirects the patient's own T cells, not a collected and manufactured cell product, so its step-up dosing and monitoring workflow differs fundamentally from CAR T therapy.
Disease Indications, Staging & Pre-Transplant Risk Stratification
Quick Clinical Summary: Determining transplant or cellular-therapy suitability balances disease biology, treatment goal, prior therapy, organ reserve, infection risk, performance, psychosocial resources, donor or product feasibility, and patient preferences. Autologous HCT supplies marrow rescue after intensive therapy; allogeneic HCT adds a donor immune effect. CAR T, TIL, NK-cell approaches, bispecific antibodies, gene-modified therapies, and DLI differ in source, mechanism, timing, and toxicity. HCT-CI informs risk but does not dictate eligibility or conditioning intensity by itself.
1. Autologous HCT: Treatment Logic and Indications
Autologous HCT permits high-dose therapy followed by reinfusion of the patient’s collected hematopoietic cells. It avoids allogeneic GVHD and does not provide a donor graft-versus-malignancy effect. Major indications include transplant-eligible multiple myeloma; selected relapsed lymphomas with chemosensitive disease; selected germ-cell tumors; and a smaller set of severe autoimmune diseases in specialized programs. Disease era, prior therapy, response, comorbidity, fertility goals and availability of CAR T or other alternatives determine timing. Age, one PET response, or one renal-dose rule is not an automatic eligibility boundary.
2. Allogeneic HCT: Treatment Logic and Indications
Allogeneic HCT provides donor hematopoiesis plus immune-mediated graft-versus-malignancy or immune-system replacement. It is used in selected acute leukemias, MDS/MPN and myelofibrosis, severe aplastic anemia, marrow-failure syndromes, hemoglobinopathies, primary immune deficiencies and other inherited disorders. The choice depends on disease genetics and measurable residual disease, remission/response, nontransplant alternatives, donor/platform, expected relapse and non-relapse risk, organ and functional reserve, infection, access and patient goals.
Examples are conditional: adverse-risk AML or persistent MRD can strengthen an allogeneic recommendation; a matched-sibling graft can be preferred in selected severe aplastic anemia; and gene therapy may compete with allogeneic HCT for selected hemoglobinopathies. Confirm the current disease guideline rather than turning an example into a universal transplant indication.
3. CAR T-Cell Therapies: FDA-Approved Products & Indications
Chimeric Antigen Receptor (CAR) T-cell therapy involves collecting autologous T lymphocytes via leukapheresis, genetically engineering them ex vivo with a viral vector to express a synthetic receptor targeting a tumor-surface antigen, expanding them, and re-infusing them following lymphodepleting chemotherapy.
| Target and disease family | Product examples | High-yield distinction |
|---|---|---|
| CD19 B-cell malignancies | Axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, lisocabtagene maraleucel | Products differ in construct, manufacturing, age range, disease indication, prior-therapy requirements, dosing, and toxicity instructions; they are not interchangeable. |
| BCMA multiple myeloma | Idecabtagene vicleucel, ciltacabtagene autoleucel | Prior-therapy requirements and safety instructions are product-specific and can change with supplemental approvals. |
Label discipline: FDA indications evolve faster than certification guides. For a real patient, verify the current prescribing information rather than inferring eligibility from target antigen or a memorized line-of-therapy rule.
4. Cellular Therapy Modalities Beyond CAR T
The outline expects more than a list of CAR T products. Link each modality to its source, mechanism, and nursing workflow:
| Modality | What it does | Nursing and assessment implications |
|---|---|---|
| Tumor-infiltrating lymphocytes (TILs) | Autologous lymphocytes are harvested from tumor, expanded, and reinfused after lymphodepletion; some regimens include cytokine support. | Coordinate tumor procurement and manufacturing, assess fitness for lymphodepletion/supportive therapy, and monitor capillary leak, infection, cytopenia, and organ toxicity per product/regimen. |
| NK-cell therapy | Uses innate cytotoxic cells from autologous, allogeneic, cord, or engineered sources. | Source and construct determine persistence, compatibility, conditioning, and toxicity surveillance; do not assume every NK product follows a commercial CAR T pathway. |
| Bispecific antibody | Redirects a patient's endogenous T cells by binding CD3 and a tumor antigen; it is an administered drug, not a collected cell product. | Step-up dosing, infection/cytopenia risk, CRS and neurologic monitoring, and outpatient eligibility are product- and protocol-specific. |
| Gene-modified hematopoietic cells | Autologous stem cells are edited or transduced to correct or compensate for disease biology, then infused after conditioning. | Preserve chain of identity, teach infertility and conditioning risks, monitor engraftment, and support required long-term follow-up for gene-modified products. |
| Donor lymphocyte infusion (DLI) | Donor lymphocytes augment graft-versus-malignancy or address selected mixed-chimerism situations after allogeneic HCT. | Balance intended immune effect against GVHD and marrow-aplasia risk; confirm disease/chimerism context and ordered dose. |
5. Matching the Modality to the Clinical Question
Candidates who can define each modality still lose items that ask what changes for the patient and the nurse when one is chosen over another. Two comparisons carry most of that weight.
Autologous HCT versus CAR T for the same relapsed lymphoma patient. Both begin with an apheresis collection, and there the similarity ends. Autologous HCT delivers high-dose conditioning with the collected cells as marrow rescue: the toxicity is regimen-related - mucositis, prolonged aplasia, infection during the neutropenic window - and it is delivered on a schedule the program controls. CAR T delivers a living drug after lymphodepletion: the toxicity is immune-mediated and clusters in the first two to four weeks as CRS, ICANS, and prolonged cytopenias, the treatment calendar depends on a manufacturing slot the program does not control, and the patient must remain near the treating center under product-specified restrictions. The caregiver burden, the monitoring plan, the emergency teaching, and the long-term follow-up obligations differ accordingly.
Allogeneic HCT versus gene therapy for a hemoglobinopathy. Both require conditioning and both aim at durable correction, but allogeneic HCT introduces a donor immune system with its graft-versus-host disease risk, its immunosuppression, and its donor availability constraint, while an autologous gene-modified product removes GVHD risk and the donor search but adds manufacturing dependency, its own conditioning toxicity including infertility, and mandated long-term follow-up for the gene-modified product. Teaching, consent, and survivorship planning diverge substantially even though the conditioning experience looks similar from the bedside.
The generalizable rule for the exam is that modality determines the toxicity window, the calendar, the setting, and the follow-up obligation - and stems usually test one of those four, not the mechanism.
Which of the following patients represents the most appropriate indication for Autologous Hematopoietic Cell Transplantation (Auto-HCT)?
An adult patient with relapsed/refractory mantle cell lymphoma following chemoimmunotherapy and a BTK inhibitor (ibrutinib) is being evaluated for cellular therapy. Which FDA-approved CAR T-cell product is specifically indicated for this clinical scenario?